Good reasons for confidential drug prices

Tidsskr Nor Laegeforen. 2019 Mar 11;139(5). doi: 10.4045/tidsskr.19.0106. Print 2019 Mar 12.
[Article in English, Norwegian]
No abstract available

MeSH terms

  • Confidentiality*
  • Cost-Benefit Analysis
  • Drug Costs*
  • Health Policy
  • Health Priorities
  • Humans
  • Norway